SOURCES SOUGHT
B -- MethylSeq Capture, Bisulfite Treatment, Sequencing and Analysis of gDNA from human subjects
- Notice Date
- 3/5/2015
- Notice Type
- Sources Sought
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- HHS-NIH-NHLBI-CSB-SBSS-(HG)-2015-086-DLM
- Archive Date
- 3/25/2015
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- Total Small Business
- Description
- This Sources Sought Notice (SS) is for information and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the National Heart, Lung, and Blood Institute (NHLBI). The purpose of this SS is to identify qualified small business concerns [including Small Disadvantaged Businesses (SDB), Woman-owned Small Businesses (WOSB), Historically Underutilized Business Zone (HUBZone) Small Businesses, Veteran-Owned Small Businesses (VOSB) and Service-Disabled Veteran-owned Small Businesses (SDVOSB] that are interested in and capable of providing: MethylSeq Capture, Bisulfite Treatment, Sequencing and Analysis of gDNA from human subjects The NHLBI does not intend to award a contract on the basis of responses nor otherwise pay for the preparation of any information submitted. As a result of this Sources Sought notice, the NHLBI may issue a Request for Quote (RFQ). THERE IS NO SOLICITATION AVAILABLE AT THIS TIME. However, should such a requirement materialize, no basis for claims against NHLBI shall arise as a result of a response to this Sources Sought notice or the NHLBI's use of such information as either part of our evaluation process or in developing specifications for any subsequent requirement. The NHLBI is seeking capability statements from all eligible small business concerns [particularly Small Disadvantaged Businesses (SDB), Woman-owned Small Businesses (WOSB), Historically Underutilized Business Zone (HUBZone) Small Businesses, Veteran-Owned Small Businesses (VOSB) and Service-Disabled Veteran-owned Small Businesses (SDVOSB)] under the North American Industry Classification System (NAICS) code 541712, Research and Development in the Physical, Engineering, and Life Sciences (except biotechnology). Based on the responses received from this SOURCES SOUGHT announcement, the proposed acquisition may be solicited as a Total Small Business Set-Aside. All eligible small business concerns responding to this Sources Sought Announcement must have the capabilities to provide goods and services as stated below. BACKGROUND : The National Institute of Health (NIH) mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The National Human Genome Research Institute (NHGRI) mission has expanded to encompass a broad range of studies aimed at understanding the structure and function of the human genome and its role in health and disease. The NHGRI/DIR Cardiovascular Disease Section (CDS) and the NHGRI/DIR Social Epidemiology Research Unit conducts a broad program of clinical and translational research seeking a greater understanding of the genomic basis of human cardiovascular disease. A major component of the research centers is understanding epigenetic modifications contributing to cardiovascular disease phenotypes such as resistant hypertension and coronary calcification. PURPOSE: The goals of the NHGRI/DIR Cardiovascular Disease Section (CDS) and NHGRI/DIR Social Epidemiology Research Unit (SERU) include identifying sites of epigenetic modifications contributing to cardiovascular disease endpoints such as resistant hypertension and coronary calcification. Epigenetic modifications such as DNA methylation have been implicated in cardiovascular disease, including atherosclerosis. DNA methylation polymorphisms may be used as an early biomarker of atherosclerosis since they are present before lesions are observed, which may provide an early tool for detection and risk prevention Therefore, it is an essential component of the GENE-FORECAST® study's in-depth cardiovascular phenotyping. DNA methylation (a biochemical process where a methyl group is added to the cytosine or adenine DNA nucleotides) is a primary mechanism of epigenetic modification. Currently, bisulfite treatment of methylated DNA followed by next-generation sequencing (Methyl-Seq) is the gold standard experimental technique for analysis of DNA methylation. Methyl-Seq experiments can focus either on the whole genome or on specific regions of the genome known to be affected by DNA methylation (the methylome). Procurement : 1. Library Construction Genomic DNA samples from 94 human subjects (Minimum 6 ug high-quality gDNA per subject); 188 total samples for library preparation (2 per subject - bisulfite treated and untreated samples); Agilent SureSelectXT Human MethylSeq capture and Illumina barcoded library generation; and 188 total libraries (94 bisulfite-treated, 94 non-treated). Contractor's Requireme nt : 1. The Contractor shall use Illumina Sequencing, approximately 80x coverage (based on 84 Mb capture) with over 6.5 Gb of data per sample Paired-end reads, Minimum read length 100 bp 188 samples total for sequencing; 2. The Contractor shall provide analysis: FASTQ Raw Sequence Files; Alignments to reference genome; coverage characterization of the reference Comparative SNP to identify bisulfite conversions; and Web-based ActiveSite Viewer for data sorting and refinement Analysis consultation; and 3. The Contractor shall provide a standard turnaround, 14-16 weeks. Shipping : • DNA samples will be shipped using gel ice in a Saf-T-Pak container. Anticipated Period of Performance : Base Year: 12 Months Capability Statement /Information : Interested parties are expected to review this notice to familiarize itself with the requirements of this project. Failure to do so will be at your firm's own risk. The following information shall be included in the capability statement: 1. A general overview of the respondents' opinions about the difficulty and /or feasibility of the potential requirement, and any information regarding innovative ideas or concepts. 2. Information in sufficient details of the respondents' (a) staff expertise, including their availability, experience, and formal and other training; (b) current in-house capability and capacity to perform the work; (c) prior completed projects of similar nature; (d) corporate experience and management capability; and (e) examples of prior completed Government contracts, references, and other related information. 3. The respondents' DUNS number, organization name, address, point of contact, and size and type of business (e.g., 8(a), HUBZone, etc) pursuant to the North American Industry Classification System (NAICS) code: 541712, Research and Development in the Physical, Engineering, and Life Sciences (except biotechnology) small business size standard is 500. 4. Any other information that may be helpful in developing or finalizing the requirements of the potential acquisition. 5. The capability statement shall not exceed 20 single-sided pages (including all attachments, resumes, charts, etc.) presented in single-space and using a 12-point font size minimum, in either Microsoft Word or Adobe Portable Document Format (PDF), with 8-1/2 by 11 inch paper size, and 1 inch top, bottom, left and right margins. 6. All proprietary information should be marked as such. Statements should also include an indication of current certified small business status; this indication should be clearly marked on the first page of your capability statement (preferably placed under the eligible small business concern's name and address). Responses will be reviewed only by NIH personnel and will be held in a confidential manner. Closing Statement : All capability Statements sent in response to this SOURCES SOUGHT notice must be submitted electronically (via email) to Dorothy Maxwell, Contracting Officer, at maxwelld@mail.nih.gov in either MS Word or Adobe Portable Document Format (PDF), by March 10, 2015, 7:30 A.M., EASTERN TIME under Solicitation Number: HHS-NIH-NHLBI-CSB-SBSS-(HG)-2015-086-DLM. FAXES ARE NOT ACCEPTED. All responses must be received by the specified due date and time in order to be considered.This Sources Sought Notice (SS) is for information and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the National Heart, Lung, and Blood Institute (NHLBI). The NHLBI does not intend to award a contract on the basis of responses nor otherwise pay for the preparation of any information submitted. As a result of this notice, the NHLBI may issue a Request for Quote (RFQ). THERE IS NO SOLICITATION AVAILABLE AT THIS TIME. However, should such a requirement materialize, no basis for claims against NHLBI shall arise as a result of a response to this notice or the NHLBI's use of such information as either part of our evaluation process or in developing specifications for any subsequent requirement. "Disclaimer and Important Notes. This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality. No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s)."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/HHS-NIH-NHLBI-CSB-SBSS-(HG)-2015-086-DLM/listing.html)
- Place of Performance
- Address: NIH Location and Contractor's Location, United States
- Record
- SN03659714-W 20150307/150305233915-31bd7b2ab9984c68d7330c6c2ae511cf (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |